STOCKHOLDERS’ EQUITY (Tables)
|
3 Months Ended |
Sep. 30, 2022 |
|---|
| Equity [Abstract] |
|
| SCHEDULE OF STOCK WARRANT ACTIVITY |
Warrant
detail for the three months ended September 30, 2022 is reflected below:
SCHEDULE
OF STOCK WARRANT ACTIVITY
| |
|
Number of Warrants |
|
|
Weighted Average Exercise Price Per Warrant |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Warrants outstanding and exercisable at June 30, 2022 |
|
|
1,455,119 |
|
|
$ |
6.10 |
|
|
|
|
|
| Warrants issued |
|
|
1,071,430 |
|
|
$ |
7.00 |
|
|
|
|
|
| Warrants cancelled |
|
|
(83,205 |
) |
|
$ |
4.00 |
|
|
|
|
|
| Warrants outstanding and exercisable at September 30, 2022 |
|
|
1,371,914 |
|
|
$ |
6.23 |
|
|
|
4.18 |
|
Warrant
detail for the three months ended September 30, 2021 is reflected below:
| |
|
Number of Warrants |
|
|
Weighted Average Exercise Price Per Warrant |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Warrants outstanding and exercisable at June 30, 2021 |
|
|
214,883 |
|
|
$ |
4.49 |
|
|
|
|
|
| Warrants issued |
|
|
1,071,430 |
|
|
$ |
7.00 |
|
|
|
|
|
| Warrants outstanding at September 30, 2021 |
|
|
1,286,313 |
|
|
|
6.58 |
|
|
|
4.61 |
|
| Warrants exercisable at September 30, 2021 |
|
|
968,670 |
|
|
$ |
6.44 |
|
|
|
4.48 |
|
|
| SCHEDULE OF STOCK OPTIONS ACTIVITY |
Activity
in the Company’s stock options during the three months ended September 30, 2022 and related balances outstanding as of that date
are reflected below:
SCHEDULE
OF STOCK OPTIONS ACTIVITY
| |
|
Number of Shares |
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Outstanding at June 30, 2022 |
|
|
503,433 |
|
|
$ |
11.03 |
|
|
|
|
|
| Granted |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Exercised |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(3,500 |
) |
|
$ |
13.60 |
|
|
|
|
|
| Outstanding and exercisable at September 30, 2022 |
|
|
499,933 |
|
|
$ |
11.02 |
|
|
|
4.31 |
|
Activity
in the Company’s stock options during the three months ended September 30, 2021 and related balances outstanding as of that date
are reflected below:
| |
|
Number of Shares |
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Outstanding at June 30, 2021 |
|
|
531,205 |
|
|
$ |
11.02 |
|
|
|
|
|
| Granted |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Exercised |
|
|
(3,400 |
) |
|
$ |
4.65 |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(2,626 |
) |
|
$ |
13.60 |
|
|
|
|
|
| Outstanding at September 30, 2021 |
|
|
525,179 |
|
|
|
11.05 |
|
|
|
6.32 |
|
| Exercisable at September 30, 2021 |
|
|
499,533 |
|
|
$ |
10.97 |
|
|
|
6.25 |
|
|
| SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY |
Activity
in RSUs during the three months ended September 30, 2022 and related balances outstanding as of that date are reflected below:
SCHEDULE
OF RESTRICTED STOCK UNITS ACTIVITY
| |
|
Number of Shares |
|
|
Weighted Average Grant date Fair Value |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Outstanding at June 30, 2022 |
|
|
304,221 |
|
|
$ |
6.06 |
|
|
|
|
|
| Granted |
|
|
5,034 |
|
|
$ |
2.70 |
|
|
|
|
|
| Vested and settled |
|
|
(1,678 |
) |
|
$ |
2.70 |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(34,679 |
) |
|
$ |
7.06 |
|
|
|
|
|
| Outstanding at September 30, 2022 |
|
|
272,898 |
|
|
$ |
5.89 |
|
|
|
1.53 |
|
Activity
in RSUs during the three months ended September 30, 2021 and related balances outstanding as of that date are reflected below:
| |
|
Number of Shares |
|
|
Weighted Average Grant date Fair Value |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Outstanding at June 30, 2021 |
|
|
131,652 |
|
|
$ |
9.25 |
|
|
|
|
|
| Granted |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(4,683 |
) |
|
$ |
8.88 |
|
|
|
|
|
| Outstanding at September 30, 2021 |
|
|
126,969 |
|
|
$ |
9.26 |
|
|
|
2.59 |
|
|
| SCHEDULE OF STOCK-BASED COMPENSATION EXPENSES |
The
following table summarizes stock-based compensation expense for employee and non-employee stock option and RSU grants:
SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSES
| |
|
2022 |
|
|
2021 |
|
| |
|
Three Months Ended
September 30, |
|
| |
|
2022 |
|
|
2021 |
|
| Research and development |
|
$ |
26,000 |
|
|
$ |
36,000 |
|
| Selling and administrative |
|
|
69,000 |
|
|
|
164,000 |
|
| Total stock-based compensation expense |
|
$ |
95,000 |
|
|
$ |
200,000 |
|
|